Osteosarcoma, Proteomics
Conditions
Brief summary
Retrospectively collected 400 cases of clinical data and pathological paraffin specimens of osteosarcoma, chondrosarcoma (control) and endogenous chondroma (control) in our hospital from 2008 to 2014, combined with high-pressure cycle-satellite scanning mass spectrometry (PCT-SWATH) Molecular typing of osteosarcoma and prediction of targeted therapy, the establishment of a new molecular classification based on proteomics for osteosarcoma to predict the chemotherapy response and recurrence risk of osteosarcoma. Clinical osteosarcoma patients include as many types as possible: pre-chemotherapy, post-chemotherapy, recurrence, and metastasis. The study did not involve vulnerable groups, and it was taken as a postoperative wax specimen for patients, which had no health, life and other effects on patients. Study application exemption from informed consent.
Interventions
DRUGChemotherapy
all osteosarcoma patients will give regular chemotherapy for osteosarcoma, the protocol is the same as Methotrexate+Doxorubicin+Cisplatin.
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* all osteosarcoma patients in our hospital * received Methotrexate+Doxorubicin+Cisplatin protocol chemotherapy
Exclusion criteria
* non-chemotherapy patients * bio-specimen not completed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| proteomics changes | 2 years | Study of changes in proteomes in tumor cells by high-throughput proteomics analysis |
Countries
China
Contacts
Primary Contactzhan Wang, Dr.
Backup ContactXiaobo Yan
Outcome results
None listed